EuroPCR 2023 | More Evidence in Favor of Renal Denervation

This study included 219 patients with uncontrolled essential hypertension who had received at least two antihypertensive drugs. All of them underwent a renal angiography and were randomized to the renal denervation group or the control group.

EuroPCR 2023 | Stenting en chimenea vs BASILICA para la prevención de obstrucción coronaria durante el TAVI

Denervation was performed using the SyMapCath I catheter and the SYMPIONEER S1 generator/stimulator.

Mean patient age was 45 years old, and 87% of subjects were male.

The composite primary endpoint was a decrease in-office systolic blood pressure below 140 mmHg for noninferiority with the control group and changes in antihypertensive drugs in both number of drugs and doses at 6 months.

In-office systolic blood pressure was approximately 159 mmHg. After denervation, it decreased on average 25.2 mmHg in those who received denervation, and 27.3 mmHg in the control group. The difference was 2.69% (95% confidence interval: 4.11% to 9.83%), reaching noninferiority with a 10-% margin.

The drug index increased in both groups, indicating the need for more medication in higher doses to achieve blood pressure control, being lower in those who underwent denervation (4.37 vs. 7.61; p = 0.003).

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

Drug adherence—analyzed by urinalysis—was high and similar in both groups (around 90% at 6 months).

In terms of procedural safety, no patient died and there was no severe renal artery injury in those who underwent denervation. Major adverse events were reported in 10% of those who underwent denervation vs. 9.2% (p = 0.823).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Reference: The SMART Study, presentado por el Dr. Jie Wang en el Congreso EuroPCR 2023, realizado en París, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....